Search

Your search keyword '"Buttinelli C"' showing total 272 results
Start Over Author "Buttinelli C"
272 results on '"Buttinelli C"'

51. Use of Bacille Calmette-Guerin (BCG) in multiple sclerosis

Author

Kruisdijk, J. J. M., primary, Linssen, W. H. J. P., additional, Ristori, G., additional, Giugni, E., additional, Bastianello, S., additional, Buttinelli, C., additional, Perna, A., additional, Salvetti, M., additional, Buzzi, M. G., additional, Sabatini, U., additional, Viselli, F., additional, Ruggieri, S., additional, and Colonnese, C., additional

Published
2000
Full Text
View/download PDF

52. Use of Bacille Calmette-Guerin (BCG) in multiple sclerosis

Author

Ristori, G., primary, Buzzi, M. G., additional, Sabatini, U., additional, Giugni, E., additional, Bastianello, S., additional, Viselli, F., additional, Buttinelli, C., additional, Ruggieri, S., additional, Colonnese, C., additional, Pozzilli, C., additional, and Salvetti, M., additional

Published
1999
Full Text
View/download PDF

58. 3-31-15 The effect of two different doses of ricombinant interferon beta-1a on relapses and total lesion volume in relapsing-remitting multiple sclerosis over the 24 month treatment period

Author

Koudriavtseva, T., primary, Pozzilli, C., additional, Bastianello, S., additional, Gasperini, C., additional, Galgani, S., additional, Bagnato, F., additional, Mainero, C., additional, Millefiorini, E., additional, Buttinelli, C., additional, and Fieschi, C., additional

Published
1997
Full Text
View/download PDF

76. Serial study of gadoliniumDTPA MRI enhancement in multiple sclerosis

Author

Bastianello, S., Pozzilli, C., Bernardi, S., Bozzao, L., Fantozzi, L. M., Buttinelli, C., and Fieschi, C.

Abstract

We performed serial baseline and gadolinium (Gd)-DTPA-enhanced MRI in 4 patients with definite multiple sclerosis. Studies were performed every month for a total of 4 scans. We obtained short TR/short TE sequences at 10 and 60 minutes after Gd-DTPA injection. All patients had multiple hyperintense lesions seen on baseline MRI with long TR/short and long TE. There was Gd-DTPA enhancement in new, enlarging, and preexisting lesions that were unchanged in size. The enhancing lesions were always seen on T2-weighted images. There was no difference in enhancement between the 10- and 60-minute studies. Six of 85 preexisting lesions enhanced whereas all new or enlarging lesions enhanced. Enhancement persisted in only of the new or enlarging lesions, suggesting that MR enhancement is a transient phenomenon due to local temporary blood-brain barrier breakdown. Our data indicate that Gd-DTPA enhancement monitoring is more sensitive than unenhanced MRI for detecting disease activity in MS.

Published
1990

78. Down-regulation of cell-surface CD4 co-receptor expression and modulation of experimental allergic encephalomyelitis.

Author

Fiori, P, Ristori, G, Cacciani, A, Buttinelli, C, Falcone, M, Di Giovanni, S, Montesperelli, C, Pozzilli, C, and Salvetti, M

Abstract

Pre-immunization with autoantigens confers resistance in experimental models of autoimmune diseases. Since non-self molecules can also be protective, it is conceivable that part of the effect rests on a non-specific attenuation of the immune response. This study is aimed at identifying mechanisms by which pre-immunization with a moiety suspended in incomplete Freund's adjuvant (IFA) protects from experimental allergic encephalomyelitis (EAE). Lewis rats were immunized with each of either concanavalin A, lipopolysaccharide, bovine serum albumin, 70 or 65 kDa heat shock proteins, or myelin basic protein. All moieties were given in IFA 3 weeks prior to EAE induction. Serial cytofluorimetric monitoring of B cells and of the alpha beta TCR+, CD4+, CD8+, CD45high and CD45low cells was performed. IFN-gamma and IgG1 production was evaluated in parallel. All moieties were able to attenuate or abrogate the clinical signs of EAE. At day 4 and 10 after EAE induction, the surface expression of the CD4 molecule was down-regulated on T lymphocytes. This down-regulation was most evident in animals with the highest degree of clinical protection. By day 21 post-immunization, CD4 expression was restored. The same animals also showed an increase in the B cell percentage and Th2-related IgG1 production while IFN-gamma secretion was reduced. Pre-immunization with diverse antigens suspended in IFA confers resistance to EAE induction. The down-regulation of the CD4 co-receptor accompanied by events suggestive of an immune deviation may be a general mechanism that contributes to the protection.

Published
1997
Full Text
View/download PDF

79. Platelet in vivo aggregation and aging

Author

Paolucci, S., Buttinelli, C., Giovanni Lucignani, and Prencipe, M.

Subjects
Adult, Aging, Platelet Aggregation, Humans, Middle Aged
Published
1984

88. Suppressor cell activity and T-cell subsets in multiple sclerosis

Author

Buttinelli C, Barnaba V, Benvenuto R, Bernardi S, Massimo Levrero, Mg, Grasso, Prencipe M, and Fieschi C

Subjects
adolescent, adult, antibodies, blood/immunology, female, helper-inducer, humans, male, middle aged, monoclonal, multiple sclerosis, phenotype, physiology, regulatory, t-lymphocytes, Antibodies, Monoclonal, T-Lymphocytes, Helper-Inducer, T-Lymphocytes, Regulatory

89. Evolution and severity markers in 233 MS patients

Author

Bernardi, S., Buttinelli, C., maria grazia grasso, Millefiorini, E., Pace, A., Prencipe, M., and Fieschi, C.

Subjects
Adult, Disability Evaluation, Female, Follow-Up Studies, Humans, Male, Middle Aged, Multiple Sclerosis, diagnosis, Adult, Male, Disability Evaluation, Multiple Sclerosis, Humans, Female, Middle Aged, Follow-Up Studies
Abstract

Clinical data of 233 patients (202 definite and 31 probable MS) have been examined in relation to the following prognostic indicators: sex, age at onset, poussè frequency, interval between the first two relapses, initial symptomatology. Regression analysis technique and covariate analysis have been used versus the latest Expanded Disability Status Scale of each patients. Onset at younger age and a longer interval between the first two episodes have resulted statistically significant for a more favourable prognosis. The shift from a remitting toward a progressive course appears to happen within the first five years in 60% of the cases.

90. Human recombinant interferon beta in the treatment of relapsing-remitting multiple sclerosis: preliminary observations

Author

Fieschi, C., Pozzilli, C., Bastianello, S., Koudriavtseva, T., claudio gasperini, Bozzao, A., Galgani, S., Paolillo, A., Millefiorini, E., and Buttinelli, C.

Subjects
Adult, Male, Multiple Sclerosis, Adjuvants, Immunologic, Adolescent, Recurrence, Humans, Female, Interferon-beta, Middle Aged, Magnetic Resonance Imaging, Recombinant Proteins
Abstract

An open comparative, randomized trial with recombinant human interferon beta (r-hIFN-beta) involving 72 patients with clinically definite and/or laboratory-supported relapsing-remitting MS is in progress at the University 'La Sapienza' and at the S. Camillo Hospital of Rome. After a 6 month period of clinical and magnetic resonance imaging (MRI) observation (baseline findings), patients are randomly assigned to one of two treatment groups receiving 3 or 9 MIU of recombinant human IFN-beta (r-hIFN-beta) self-administered by subcutaneous injection three times a week for 6 months. All patients are examined by MRI with and without gadolinium (Gd-DTPA) every 4 weeks for the entire duration of the study (12 months). The main aim of the study is to test the hypothesis that r-hIFN-beta may halt or slow the progression of the disease by showing a significant reduction in MRI activity. This will be achieved by comparing pre and post-treatment periods. As an additional clinical end point, the exacerbation rate during these two periods will be compared. This study began in June 1993 and the final analysis of MRI data is planned for the spring of 1995.

95. Pathophysiology of ischemic brain disease

Author

Fieschi, Cesare, Vittorio Di Piero, Lenzi, Gian Luigi, pantano patrizia, Giubilei, Franco, Buttinelli, C., and Carolei, A.

Subjects
Tomography, Emission-Computed, Single-Photon, Glucose, Cerebrovascular Circulation, Animals, Brain, Humans, Energy Metabolism, Brain Ischemia
Abstract

In this article, we review and discuss the pathophysiology of brain ischemia, focusing on requirements of cerebral metabolism, biochemical characterization of the energy reserve, and autoradiographic and tomographic methods for in vivo evaluation of cerebral blood flow and metabolism. We propose new therapeutic strategies for the management of the acute phase of stroke, based on diagnostic protocols that include clinical evaluation, noninvasive study of neck and intracranial arteries, brain computed tomography, and single-photon emission computed tomography. The ideal therapeutic trial should combine early thrombolysis and active brain protection against those biochemical mechanisms leading to irreversible neuronal damage.

Catalog

Books, media, physical & digital resources
See catalog results